ImmunoGen Announces Virtual 2020 Annual Meeting of Shareholders
The Annual Meeting will be held on
Shareholders will not be able to attend the Annual Meeting in person. Instead, shareholders can attend the Annual Meeting by accessing the meeting center at www.virtualshareholdermeeting.com/IMGN2020.
Shareholders of Record: Shareholders of record at the close of business on
April 13, 2020(i.e., shares are held in the shareholder’s own name in the records of the Company’s transfer agent, Broadridge Corporate Issuer Solutions, Inc.(“Broadridge”)) can attend the virtual Annual Meeting by accessing the meeting center at www.virtualshareholdermeeting.com/IMGN2020 and entering the 16-digit control number on the proxy card or Notice Regarding the Availability of Proxy Materials previously received. Shareholders of record that have misplaced their control number can call Broadridge at (855) 697-4961.
Beneficial Owners: Beneficial owners of the Company’s common stock at the close of business on
April 13, 2020(i.e., shares are held by the shareholder’s broker in “street name”) can attend the Annual Meeting by accessing the meeting center at www.virtualshareholdermeeting.com/IMGN2020 and entering the 16-digit control number found on the notice and instructions received from their broker or other nominee.
If a shareholder does not have their 16-digit control number, the shareholder will be able to access and listen to the Annual Meeting as a guest, but the shareholder will not be able to vote their shares or submit questions during the Annual Meeting.
Instructions on how to connect to the Annual Meeting and participate via the Internet, including how to demonstrate proof of stock ownership, ask questions, and vote, are posted at www.virtualshareholdermeeting.com/IMGN2020.
Shareholders will also be able to submit questions through the platform being used for the Annual Meeting. Shareholders may ask questions that are confined to matters properly presented at the Annual Meeting and of general concern to the Company.
The Annual Meeting will begin promptly at
Whether or not a shareholder plans to attend the Annual Meeting, the Company urges shareholders to vote and submit their proxy in advance of the Annual Meeting by one of the methods described in the proxy materials for the Annual Meeting.
A notice regarding this change to a virtual meeting format (the “Notice”) is being filed with the
If shareholders encounter any difficulties accessing the virtual meeting during the check-in or meeting time, please call the technical support number that will be posted on the virtual Annual Meeting log in page.
The virtual Annual Meeting platform is fully supported across browsers (Internet Explorer, Firefox, Chrome, and Safari) and devices (desktops, laptops, tablets, and cell phones) running the most updated version of applicable software and plugins. Shareholders should ensure that they have a strong internet connection wherever they intend to participate in the Annual Meeting. Shareholders should also give themselves plenty of time to log in and ensure that they can hear streaming audio prior to the start of the Annual Meeting.
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
INVESTOR RELATIONS AND MEDIA